Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Daito Pharmaceutical Co., Ltd. ( (JP:4577) ) has issued an update.
Daito Pharmaceutical reported nine-month net sales of ¥36.7 billion, essentially flat year on year, but significantly improved profitability, with operating profit up 47.2% and profit attributable to owners of parent up 86.2%. Earnings per share rose to ¥76.53 following a prior stock split, EBITDA increased, and the equity ratio strengthened to 69.7%, reflecting a solid financial position.
The company maintained its dividend policy with a forecast total annual dividend of ¥40 per share for the year ending May 31, 2026, while revising its full-year earnings outlook. It now expects modest sales growth to ¥51.0 billion but a marked recovery in profitability, projecting operating profit of ¥3.3 billion and profit attributable to owners of parent of ¥2.5 billion, underscoring an improved earnings structure and enhanced returns capacity for shareholders.
The most recent analyst rating on (JP:4577) stock is a Hold with a Yen1509.00 price target. To see the full list of analyst forecasts on Daito Pharmaceutical Co., Ltd. stock, see the JP:4577 Stock Forecast page.
More about Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical manufacturer listed on the Tokyo Stock Exchange. The company focuses on developing and producing pharmaceutical products, and reports its results under Japanese GAAP, targeting stable growth and shareholder returns through dividends.
Average Trading Volume: 89,980
Technical Sentiment Signal: Buy
Current Market Cap: Yen43.09B
For an in-depth examination of 4577 stock, go to TipRanks’ Overview page.